LISTING AND AMENDMENT OF THE CLAIMS

Claims 1-5. (Canceled)

Claim 6. (New) A method for screening a selective inhibitor of COX-2 for likelihood of success in treating a patient having or at risk for cancer, Alzheimer's disease or atherosclerosis, comprising testing for at least two of

(a) causing increase in PPRE luciferase activity by at least 100% as manifested by at least doubling of luciferase activity based on data that have been normalized with β-galactosidase activity; (b) causing at least 50% decrease in level of or 50% downregulation of expression of Class I family of receptors tyrosine kinase; (c) causing at least 50% downregulation of expression of cyclin D1; (d) causing at least 50% downregulation of expression of HPV16 oncoproteins E6 and E7; (e) causing at least 50% increase in expression of PTEN, (f) causing at least 50% inhibition of tcf/lef/-catenin-mediated promoter activation; and (g) causing at least 50% increase in level of Nrf-2; the more of (a), (b), (c), (d), (e), (f) and (g) being met, the greater the likelihood of success.

Claim 7. (New) The method of claim 6 which is for screening a selective inhibitor of COX-2 for likelihood of success in treating a patient with colon cancer.

Claim 8. (New) The method of claim 6 which is for screening a selective inhibitor of COX-2 for likelihood of success in treating a patient with Alzheimer's disease.

Claim 9. (New) The method of claim 6 which is for screening a selective inhibitor of COX-2 for likelihood of success in treating a patient with atherosclerosis.

Claim 10. (New) The method of claim 6 which is for screening a selective inhibitor of COX-2 for likelihood of success in treating a patient with an oral premalignant lesion of the tongue.

Claim 11. (New) The method of claim 6 which is for screening a selective inhibitor of COX-2 for likelihood of success in treating cervical intraepithelial neoplasia.